Detalles de la búsqueda
1.
SER-109, an Oral Microbiome Therapy for Recurrent Clostridioides difficile Infection.
N Engl J Med;
386(3): 220-229, 2022 01 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-35045228
2.
Prevalence of Comorbid Factors in Patients With Recurrent Clostridioides difficile Infection in ECOSPOR III, a Randomized Trial of an Oral Microbiota-Based Therapeutic.
Clin Infect Dis;
77(11): 1504-1510, 2023 11 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-37539715
3.
Extended Follow-up of Microbiome Therapeutic SER-109 for Recurrent Clostridioides difficile Infection-Reply.
JAMA;
329(12): 1033-1034, 2023 03 28.
Artículo
en Inglés
| MEDLINE | ID: mdl-36976280
4.
Extended Follow-up of Microbiome Therapeutic SER-109 Through 24 Weeks for Recurrent Clostridioides difficile Infection in a Randomized Clinical Trial.
JAMA;
328(20): 2062-2064, 2022 11 22.
Artículo
en Inglés
| MEDLINE | ID: mdl-36260754
5.
Fidaxomicin versus Vancomycin in the Treatment of Clostridium difficile Infection: Canadian Outcomes.
Can J Infect Dis Med Microbiol;
2016: 8048757, 2016.
Artículo
en Inglés
| MEDLINE | ID: mdl-27366179
6.
Differences of the Fecal Microflora With Clostridium difficile Therapies.
Clin Infect Dis;
60 Suppl 2: S91-7, 2015 May 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-25922407
7.
Vancomycin, metronidazole, or tolevamer for Clostridium difficile infection: results from two multinational, randomized, controlled trials.
Clin Infect Dis;
59(3): 345-54, 2014 Aug 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-24799326
8.
Fidaxomicin versus vancomycin for Clostridium difficile infection.
N Engl J Med;
364(5): 422-31, 2011 Feb 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-21288078
9.
Renal impairment and clinical outcomes of Clostridium difficile infection in two randomized trials.
Am J Nephrol;
38(1): 1-11, 2013.
Artículo
en Inglés
| MEDLINE | ID: mdl-23796582
10.
Safety and Tolerability of SER-109 as an Investigational Microbiome Therapeutic in Adults With Recurrent Clostridioides difficile Infection: A Phase 3, Open-Label, Single-Arm Trial.
JAMA Netw Open;
6(2): e2255758, 2023 02 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-36780159
11.
Fidaxomicin attains high fecal concentrations with minimal plasma concentrations following oral administration in patients with Clostridium difficile infection.
Clin Infect Dis;
55 Suppl 2: S116-20, 2012 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-22752859
12.
Fidaxomicin preserves the intestinal microbiome during and after treatment of Clostridium difficile infection (CDI) and reduces both toxin reexpression and recurrence of CDI.
Clin Infect Dis;
55 Suppl 2: S132-42, 2012 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-22752862
13.
Treatment of first recurrence of Clostridium difficile infection: fidaxomicin versus vancomycin.
Clin Infect Dis;
55 Suppl 2: S154-61, 2012 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-22752865
14.
Fidaxomicin versus vancomycin for Clostridium difficile infection: meta-analysis of pivotal randomized controlled trials.
Clin Infect Dis;
55 Suppl 2: S93-103, 2012 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-22752871
15.
SER-109: An Oral Investigational Microbiome Therapeutic for Patients with Recurrent Clostridioides difficile Infection (rCDI).
Antibiotics (Basel);
11(9)2022 Sep 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-36140013
16.
Efficacy of fidaxomicin versus vancomycin as therapy for Clostridium difficile infection in individuals taking concomitant antibiotics for other concurrent infections.
Clin Infect Dis;
53(5): 440-7, 2011 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-21844027
17.
OPT-80 eliminates Clostridium difficile and is sparing of bacteroides species during treatment of C. difficile infection.
Antimicrob Agents Chemother;
53(1): 261-3, 2009 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-18955523
18.
A potential new tool for managing Clostridium difficile infection.
J Infect Dis;
207(10): 1484-6, 2013 May 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-23420904
19.
Cadazolid for the treatment of Clostridium difficile infection: results of two double-blind, placebo-controlled, non-inferiority, randomised phase 3 trials.
Lancet Infect Dis;
19(3): 265-274, 2019 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-30709665
20.
Sustained clinical response as an endpoint in treatment trials of Clostridium difficile-associated diarrhea.
Antimicrob Agents Chemother;
56(8): 4043-5, 2012 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-22615287